FDA warns Maison Blanche for refusing repeated requests for records on its OTC hand sanitizer.
What happened
FDA sent electronic requests for records and other information under section 704(a)(4) on August 16 and August 31, 2022, to the email in Maison Blanche's registration file. The firm did not answer those requests or later FDA emails and phone messages, including messages in September 2023 asking for a response within 24 hours. FDA said it has no indication of the quality assurance for drugs registered as manufactured at the firm's facility.
What FDA found
The company did not provide FDA with records and other information it requested about its OTC drug manufacturing.
Section 704(a)(4) of the FD&C Act (21 U.S.C. 374(a)(4))FDA says refusing to permit access to or copying of required records is a prohibited act.
Section 301(e) of the FD&C Act (21 U.S.C. 331(e))
What FDA wants
Respond within 48 hours to confirm or update the firm's registration and drug listing status and to say whether it will respond to the records request. If it no longer makes drugs, delist all previously listed drugs using the last lot expiration date as the marketing end date and deregister the facility.
Who should pay attention
- retailers and distributors that sell Hand Sanitizer Nº93 Maison Blanche
- companies that rely on FDA drug listing and registration records for supplier checks
- OTC drug manufacturers with unanswered FDA records requests
This is a summary. Read the original letter on fda.gov.